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INTRODUCTION 
Bombesin, a tetradecapeptide originally isolated from the skin of the frog Bombina 
bombina,’ elicits dose-related excessive grooming when injected centrally in rats2-‘ as 
well as other  specie^.^ The grooming induced by intracerebroventricular (i.cv.) bombesin 
in rats consists of hindlimb scratching directed primarily at the head and neck, al- 
though facial grooming, body washing, nail licking and biting, forepaw tremors, wet- 
dog shakes, and stretching also occur. Bombesin-induced grooming behavior can be 
observed within a few minutes of i.c.v. injection and continues for 30-45 minutes. 
In contrast to the grooming induced by a variety of other peptides such as ACTHI-,,, 
thyrotropin-releasing hormone, substance P, P-endorphin, and nonpeptides such as 
RX 336-M (7,8-dihydro-5’,6‘-dimethylcyclohex-5’-en0-1’,2~,8~,14 codeinone), bombesin- 
induced grooming is not inhibited by nonsedative doses of 
In keeping with multiple types of cholinergic, adrenergic, histaminic, and 
dopaminergic receptors, it is also well established that there are multiple types of opioid 
receptors. Based on observations in dogs, the existence of three types of opioid receptors 
was postulated: mu (for which morphine was the prototype), kappa (for which ketocy- 
clazocine was the prototype) and sigma (for which N-allyl-normetazocine was the pro- 
totype).l2.l3 Since then, mu and kappa types of opioid receptors have been differen- 
tiated by biochemical studies using receptor binding and visualization techniques (see, 
for example, refs. 14 and 15) and by pharmacological studies in which differences in 
acute effects, differences in the ease of antagonism by the opioid-specific antagonist 
naloxone, and the selective development of tolerance and dependence were identified 
(see refs. 16-18). Whereas sigma receptors are no longer considered to be opioid (i.e., 
naloxone is not an antagonist of effects mediated by the “sigma” receptor), a third 
type of opioid receptor has been identified primarily through in vitro studies, the delta 
re~eptor.’~ The endogenous enkephalins have been proposed as natural ligands for 
the delta receptor. 
In light of the multiple classes of opioids, we decided to examine opioids other 
than morphine for their ability to inhibit bombesin-induced grooming in rats. In our 
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preliminary s t u d i e ~ , ~ . ~ . ’ ~  it became evident that ethylketazocine (a compound struc- 
turally and pharmacologically related to ketazocine) could antagonize bornbesin-induced 
grooming. It was therefore decided to study further the role of opioid receptors in 
the modulation of bombesin-induced grooming. 
Ethylketocyclazocine, and more recently tifluadom and U-50.488 (tmns-3,4-dichloro- 
N-methyl-N-[2-(pyrrolidinyl)cyclohexy~l]benzeneace~mide)~ have been used as pro- 
totypical kappa agonists. Ethylketazocine is a benzomorphan showing selectivity for 
kappa receptors in binding assays as well as in most tests in v i m  and in vivo. It can 
act through mu receptors, however, to produce hot water tail-withdrawal analgesia and 
inhibit gastrointestinal transit in rats.’’ Tifluadom is a very interesting compound in 
that it has the structure of a benzodiazepine but little or no activity at benzodiazepine 
receptors; it has been found to be very selective for the kappa type of opioid receptor, 
h~wever.’~~’’ U-50,488 is a compound of novel structure for opioids.u In binding studies, 
U-50,488 has a selectivity of approximately 250-fold for kappa over mu or delta binding 
sites in quinea pig brain.Is It has a strictly kappa profile of activity both in v i m  and 
in vivo (see, for example, refs. 18, 24, 26, and 27). 
In this work, the role of opioid receptors in bombesin-induced grooming was in- 
vestigated by means of classical methods in opioid pharmacology: by classification 
of opioid-like compounds on the basis of their ability to inhibit the grooming elicited 
by a standard submaximal dose of bombesin; by examination of the stereospecificity 
of the interaction between the opioid and bombesin; by examination of the sensitivity 
of the opioids to naloxone; and through tolerance and cross tolerance studies. 
METHODS 
Animals and Surgery 
Male Sprague-Dawley albino rats weighing 180-200 g were each implanted with 
a stainless steel cannula (Plastic Products Co., Roanoke, VA) directed towards the lateral 
cerebral ventricle as described previously.‘ The rats were housed individually at 23 k 
1°C with free access to food and water for at least 4-7 days before testing. They were 
exposed to a 12-h timer-regulated light period from 7 A.M. to 7 P.M. 
General Procedure 
Experiments were carried out in the afternoons. At least 15 min before testing, 
the rats were transfered from their home cages and placed individually in Plexiglas 
observation boxes (22 cm long; 18 cm wide; 25 cm high). Four rats were monitored 
at a time with the aid of a portable microcomputer as described previously.”,’* Test 
compounds, with the exception of dynorphin A, were injected 15 min prior to a stan- 
dard submaximal groom-inducing dose of bombesin4 (0.1 pg, i.cv.). Dynorphin A and 
[~-Pen-2,~-Pen-S]enkephalin were given i.cv. 5 min before bombesin (0.1 pg, i.cv.). 
Quantification of Behavior 
Beginning immediately after the last bombesin or i.c.v. saline control injection, each 
rat was observed for 5 s out of every 20 s for a total of 30 min. A positive grooming 
score was given if the rat demonstrated any type of grooming behavior (e.g., scratching, 
CMEREK & COWAN: ROLE OF OPIOID RECEPTORS 293 
washing, licking, biting, etc.) during the 5-s observation period. Consequently, there 
was a total of 90 grooming episodes scored. 
Results are presented as the VoMGE (maximum number of grooming episodes scored 
as positive) f SEM. The %MGE was calculated for each rat (i.e., number of positive 
grooming scores times 100, divided by 90). Groups of at least five rats were used to 
determine each data point. Intracerebroventricular saline control animals had VoMGE 
scores of 6 f 1. If, following the pretreatment with a test compound and bombesin 
administration, the majority of rats had %MGE of less than 6, their grooming be- 
havior was said to be suppressed. Compounds were said to have the ability to antagonize 
bombesin-induced grooming only if they inhibited the scratching behavior in a dose- 
related manner at doses that did not suppress grooming behavior below i.c.v. saline 
controls. 
Absolute grooming scores were analyzed statistically by means of ANOVA followed 
by Dunnett’s test or the Mann-Whitney U-test, as appr~priate.’~ Percent inhibition of 
bombesin-induced grooming was calculated as follows: 
1 - (bombesin grooming score in opioid-pretreated rats - saline controls) 
(bombesin grooming score in saline-pretreated rats - saline controls) x loo. 
As,, values (i.e., doses at which test compounds antagonize an effect by 50%) were de- 
termined by linear regression analy~is’~ of absolute data from which saline control 
values had been subtracted. Confidence limits (95%) of A, values were also determined. 
Compounds and Injections 
The following compounds were used azidomorphine bitartrate (J. Knoll, Sem- 
melweise University of Medicine, Budapest, Hungary), bombesin (Sigma and Boehringer 
Mannheim, Indianapolis, IN), bmnazocine HCI 0. Romer, Sandoz, Basel, Switzerland), 
buprenorphine HCl (National Institute on Drug Abuse, Rockville, MD), codeine phos- 
phate (Merck Sharp & Dohme, West Point, PA), cyclazocine (Sterling-Winthrop, Rens- 
selaer, NY), dextrorphan (NIDA), dynorphin A (Penninsula Laboratories, Belmont, 
Calif.), B-endorphin (A. A. Manian, National Institute of Mental Health, Bethesda, 
MD), [~-Pen-2p-Pen-S]enkephalin (DPDPE, Penninsula), ethylketazocine methanesul- 
fonate (EKC, Sterling-Winthrop), d-EKC and I-EKC (Sterling-Winthrop), ethylmor- 
phine HCI (Merck Sharp & Dohme), heroin HCl (NIDA), ketocyclazocine methanesul- 
fonate (Sterling-Winthrop), levorphanol tartrate (Hoffmann-La Roche, Nutley, NJ), 
meperidine HCl (Sterling-Winthrop), methadone HCl (NIDA), metkephamid (R. C. 
A. Frederickson, Eli Lilly Co., Indianapolis, IN), morphine sulfate (Mallinckrodt Inc. 
St. Louis, MO), nalbuphine HCI (Endo Laboratories, Inc., Garden City, NY), nalor- 
phine HCI (Sigma), d-naloxone HCl and I-naloxone HCI (A. Jacobson, National In- 
stitutes of Health, Bethesda, MD), naloxone HCI (Endo), I-pentazocine (Sterling- 
Winthrop), phenazocine HBr (Smith Kline & French, Philadelphia, PA), quadazocine 
methanesulfonate (also known as Win 44,441-3; Sterling-Winthrop), thebaine (NIDA), 
racemic tifluadom, (+)- and (-)-tifluadom (referring to the optical rotation as mea- 
sured in ethanol; Kali-Chemi AG, Hannover, FRG), U-50,488 (trans-3.4-dichloro-N- 
methyl-N-[2-(pyrolidinyl)cyclohexyl-l]benzeneacetamide) (J. Collins, Upjohn Co., 
Kalamazoo, MI), xorphanol mesylate (H. G. Pars, Pharmaceutical Laboratories, Inc, 
Cambridge, MA), and zomepirac (McNeil Laboratories, Fort Washington, PA). 
The alkaloids were dissolved in a minimal volume of glacial acetic acid, if neces- 
sary, and diluted with saline. Tifluadom (racemic and optical isomers) were dissolved 










0 -  
in a solution of 40% propylene glycol, 10% ethanol, 5% sodium benzoate and ben- 
zoic acid, and 15% benzyl alcohol by sonication and heat. Injections were given S.C. 
in volumes of 1 ml/kg with doses calculated as the base or salt as indicated above; 
the dose of d- and I-naloxone was calculated as the free base. Aliquots of bombesin, 
DPDPE, dynorphin A, and P-endorphin were each dissolved in saline daily as needed. 
Bombesin, DPDPE. dynorphin A and P-endorphin were injected i.c.v. to hand-held, 









The following compounds given as 15 min s.c pretreatments to a standard 0.1 pg 
dose of i.c.v. bombesin did not attenuate bombesin-induced grooming at nonsedative 
doses, i.e., doses that did not suppress grooming behavior below i.c.v. saline controls 
(highest nonsedative dose used in mg/kg, sc., in parentheses): azidomorphine (0.05), 
buprenorphine (0.5), codeine (40). dextrorphan (30), ethylmorphine (loo), heroin (OS), 
levorphanol(1). meperidine (25), methadone (l), metkephamid (30), morphine (lo), 
nalbuphine (lo), naloxone (lo), and thebaine (25). P-Endorphin (10 pg, i.c.v.) given 
EN 0.1 0.32 1.0 3.2 10 32 
Dome (mg/kg, 8.c.) 
FIGURE 1. The effect of 15-min pretreatment with ethylketazocine mdhanesulfonate (EKC), 
U-50,488 (U-SO), or tifluadom (T) on the grooming induced by bombesin (0.1 pg. icv.). %MGE 
is the percentage of the maximum number of grooming episodes scored as positive during the 
30-min observation session. Data points indicate the mean f SE for 5-8 rats. BN: %MGE fol- 
lowing saline (1 ml/kg, s.c) pretreatment. 
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FIGURE 2. The effect of 15-min pretreatment with saline (1 ml/kg, sc.), the stereoisomers of 
EKC (both 0.5 mg/kg, s.c.), or the optical isomers of tifluadom (T ,  both 10 mg/kg, s.c.) on 
the grooming induced by bombesin (0.1 pg, i.c.v.). %MGE is the percentage of the maximum 
number of grooming episodes scored as positive over the 30-min observation session. Burs indi- 
cate the mean f SE for 5-8 rats; ***p < 0.001, ANOVA and Mann-Whitney U-test compared 
to saline + bombesin controls; *p = 0.02, ANOVA and Mann-Whitney U-test compared to 
(-)-tifluadom + bombesin. 
15 min before bombesin or DPDPE (1 and 5 pg, i.c.v.) given 5 min before bombesin 
also did not attenuate bombesin-induced grooming at doses that did not produce corn- 
peting behaviors (catalepsy and rearing, respectively). Zomepirac (5 mg/kg, s . ~ )  had 
no marked effect on bombesin-induced grooming. 
Bremazocine (10 mg/kg), cyclazocine (5 mg/kg), ketazocine (1 mg/kg), I-pentazocine 
(20 mg/kg), and phenazocine (0.5 mg/kg) attenuated bombesin-induced grooming sig- 
nificantly compared to saline + bombesin controls (p < 0.001; ANOVA followed by 
Dunnett's test for multiple comparisons) at nonsedative doses (VoMGE scores remained 
greater than i.cv. saline controls). Xorphanol attenuated bombesin-induced grooming 
in a dose-related manner with an ASo of 0.71 (0.41-1.21) mg/kg, S.C. Dynorphin A also 
antagonized bombesin-induced grooming in a dose-related manner with an ASo of 4.1 
(2.8-5.9) pg, i.c.v. 
FIGURE 1 shows the dose-related decrease in bombesin-induced grooming produced 
by EKC, U-50,488, and tifluadom. The As:s for EKC, tifluadom, and U-50,488 to 
antagonize bombesin-induced grooming were 0.36 (0.33-0.40), 6.61 (5.37-8.13), and 
6.80 (5.52-8.36) mg/kg, respectively. 
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TABLE 1. Naloxone Antagonism of the Effect of S.C. EKC (0.5 mg/kg), U-50,488 
(10 mg/kg), and Tifluadom (10 mg/kg) on Bombesin-induced Grooming (0.1 pg, 
i.c.v.). 
Naloxone A,, (95% C.L."), 
Opioid Agonist mg/kg, S.C. 
EKC 0.076 (0.068-0.086) 
Ti fluadom 0.12 (0.08-0.20) 
U-50,488 0.43 (0.30-0.60) 
a Confidence limit. 
Stereoselectivity of EKC and Tifluadom 
FIGURE 2 shows the stereoselectivity of EKC and tifluadom in their ability to an- 
tagonize bombesin-induced grooming. The levorotatory enantiomer, but not the dex- 
trorotatory enantiomer, of EKC inhibited bombesin-induced grooming. Whereas both 
isomers of tifluadom antagonized bombesin-induced grooming, the (+)-optical isomer 
of tifluadom was significantly more effective than the (-)-isomer. 
Sensitivity to Naloxone 
Naloxone itself, up to 10 rng/kg, had no effect on bombesin-induced grooming. 
Naloxone, however, reversed the effects of EKC, tifluadom, and U-50,488 (doses that 
inhibited bombesin-induced grooming by approximately 80%) in a dose-related manner. 
TABLE 1 shows the potency of naloxone against the effects of the three kappa agonists 
on bombesin-induced grooming. This action of naloxone was stereospecific in that 
I-naloxone (0.08 mg/kg) prevented the action of 0.5 mg/kg EKC on bombesin-induced 
grooming significantly (p < 0.01), whereas d-naloxone (0.1 mg/kg) had no effect on 
the ability of the same dose of EKC to attenuate bombesin-induced grooming (data 
not shown). 
TABLE 2. Effect of Multiple Injections of EKC or Morphine on the Ability of EKC 
to Attenuate Bombesin-induced Grooming 
Treatment' Bombesin-induced Grooming 
saline saline 68 f 3 
EKC saline 73 * 6 
EKC , EKC 85 f qd 
morphine saline 62 f 6 
mnrnhine EKC 23 f 4 
(8x1 Challenge' (VoMGE f SEM) 
saline EKC 20 * 4c 
Eight injections over consecutive days as described in RESULTS. 
Challenge with saline (1 ml/kg, s.c.) or EKC (0.5 mg/kg, s.c.) was given 19-20 h after the 
eighth injection of saline, EKC, or morphine, and 15 min before bombesin (0.1 pg, i.c.v.). 
p < 0.001, ANOVA followed by the Mann-Whitney U-test compared to saline + saline 
controls. 
p < 0.001, ANOVA followed by the Mann-Whitney U-test compared to saline + EKC 
controls. 
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lblerance Studies 
Morphine was given at 5 P.M. and 8 A.M. at doses of 10, 10, 30, 30, 100, 100, 100, 
and 100 mg per kg per injection for a total of eight injections over consecutive days 
to two groups of eight rats. EKC was given eight times over consecutive days at the 
doses of 5 ,  5 ,  10, 10,20,20,20, and 20 mg per kg per injection to two groups of rats. 
Another two groups of rats received twice-daily injections of saline (1 ml/kg, s.c) for 
four consecutive days. Beginning 19-20 h after the last of the multiple morphine, EKC, 
or saline injections, the rats were challenged with saline (1 ml/kg, s.c) or EKC (0.5 
mg/kg, s.c) and followed 15 min later with the standard dose of bombesin (0.1 pg, 
i.cv.) as indicated in TABLE 2. Multiple treatments with saline, morphine, or EKC had 
no effect on bombesin-induced grooming. Multiple injections of morphine also did 
not affect the ability of EKC to attenuate bombesin-induced grooming. However, mul- 
tiple injections of EKC decreased significantly 0, < 0.001) the ability of EKC (0.5 mg/kg) 
to inhibit bombesin-induced grooming; i.e., tolerance developed to EKC. 
DISCUSSION 
The excessive grooming (scratching) behavior elicited by a standard submaximal dose 
of bombesin was attenuated in a dose-related and stereoselective manner by opioids 
showing activity at the kappa type of receptor. These included benzomorphan anal- 
gesics; the endogenous kappa-selective opioid peptide, dynorphin A, a morphinan mixed 
agonist-antagonist analgesic of the kappa type, xorphanol; and the most kappa-receptor- 
selective opioid available, U-50,488. It is important to note that the inhibition of 
bombesin-induced grooming by these opioids occurred in a dose-related fashion and 
at doses that did not obliterate natural grooming behavior. 
In contrast, compounds whose agonist effects are thought to be mediated by the 
mu or delta types of opioid receptors were unable to affect bombesin-induced scratching 
at doses that did not completely suppress grooming behavior. Most of these compounds 
eventually prevented bombesin-induced grooming, but it was not a dose-related ef- 
fect, and grooming behavior was prevented altogether: %MGE scores were below those 
of i.cv. saline controls. These included the prototype mu-receptor agonist, morphine; 
the prototype delta-receptor agonist, DPDPE; and a mixed agonist-antagonist anal- 
gesic of the mu-type, nalbuphine. In addition, the nonopioid analgesic, zomepirac, 
had no marked effect on bombesin-induced grooming. 
Ethylketazocine, tifluadom, and U-50.488 were examined more thoroughly as pro- 
totype kappa opioid agonists in their ability to affect bombesin-induced grooming. 
All three compounds inhibited bombesin-induced grooming in a dose-related and par- 
allel manner. Ethylketazocine was approximately 18 times as potent as U-50,488 and 
tifluadom, which were equipotent. A similar potency relationship has been observed 
among EKC and U-50,488 and tifluadom in the rat tail-immersion test."." U-50,488 
was found to be 10 times less potent than EKC in the rat tail-flick test." 
Ethylketazocine was stereospecific in its ability to affect bornbesin-induced grooming 
in that the (+)-enantiomer was ineffective at doses at which the (-)-enantiomer had 
a significant effect. Tifluadom showed stereoselectivity, but not to as great an extent. 
Thus, 10 mg/kg of both the (+)- and (-)-isomers did suppress bombesin-induced 
grooming. However, (-)-tifluadom was significantly less effective than the (+)-isomer. 
The stereoselectivity of the (+)-optical isomer of tifluadom (determined in ethanol) 
for opioid receptors has been observed previously in miceJa and  monkey^.^' The (-)- 
isomer of tifluadom has some affinity for the benzodiazepine r e c e p t ~ r ~ ' . ~ ~  and may 
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inhibit bombesin through this receptor; diazepam also inhibits bombesin-induced 
grooming at nonsedative doses (unpublished observation). This could be tested easily 
by examining the ability of naloxone to antagonize the actions of (-)-tifluadom on 
bombesin-induced grooming. 
The ease at with which naloxone reversed the actions of EKC, U-50,488, and tiflu- 
adom on bombesin-induced grooming and the stereospecificity of naloxone in having 
this effect verifies that opioid receptors mediate their action. Naloxone is less potent 
at kappa than mu receptors. Its decreasing potency in antagonizing EKC, tifluadom, 
and U-50.488 may therefore correspond to the increasing relative affinity of the three 
agonists for kappa over mu receptors.26 
The development of tolerance to the ability of EKC to inhibit bombesin-induced 
grooming, taken together with the stereoselectivity, reversibility by naloxone, and the 
lack of effect of the nonopioid analgesic zomepirac indicate that opioid receptors 
mediate the attenuation of bombesin-induced scratching by analgesics. It becomes clear, 
however, based on tests of 35 opioid-like compounds with a large variety of chemical 
and pharmacological properties, that the kappa type of receptor is the only known 
opioid receptor linked to bombesin-induced grooming. Thus, mu opioid receptor 
agonists (morphine, codeine, levorphanol, heroin), mixed agonist-antagonists of the 
mu type (buprenorphine, nalbuphine), opioid antagonists (naloxone), peptides with 
mu- and delta-receptor activity @-endorphin, metkephamid, DPDPE), and chemi- 
cally related nonopioids (dextrophan, thebaine) had no effect at nonsedative doses 
in this test. However, all the compounds tested that act at the kappa-type of opioid 
receptor were effective. Furthermore, the lack of tolerance to EKC in rats that received 
multiple injections of morphine is in agreement with the kappa-receptor specificity 
of opioid link to bombesin-induced scratching. 
How- 
ever, its kappa receptor activity in vivo has been questioned. The dose-related antagonism 
of bombesin-induced grooming may be used as new evidence of a kappa-receptor- 
mediated effect of supraspinally administered dynorphin A. The inhibition of bombesin- 
induced grooming occurred at doses similar to those at which dynorphin A increased 
feeding in r a P  (another effect thought to be mediated by kappa receptors). Similarly, 
the attenuation of bombesin-induced grooming by xorphanol may be used as further 
evidence of the kappa agonist nature of this compound.38 
Having established that opioids act through kappa receptors to affect bombesin- 
induced scratching, we can speculate on the role of bombesin and opioids in scratching 
behavior. It is known that low doses of opioids acting at mu receptors (e.g., morphine 
and levorphanol) often cause scratching behavior in animals, and itching in humans. 
Bombesin given i.c.v. to morphine-dependent rhesus monkeys produces scratching be- 
havior that is similar to, but more intense, than that observed following low doses of 
morphine in drug-naive monkeys (ref. 5 and unpublished observations). The itching 
produced by low doses of morphine is thought to be due to the release of histamine; 
however, it is not clear that histamine is the sole cause of this effect. In contrast, the 
acute administration of kappa opioids does not elicit scratching behavior. However, 
abstinence or naloxone-induced withdrawal behavior following the chronic adminis- 
tration of kappa opioids includes scratching as a prominent response. *8.38 This behavior, 
and the possible role of bombesin in its production, needs to be studied further. Simi- 
larly, the role of bombesin in different types of pruritus and a possible link to kappa 
opioids should be investigated further. For example, opioids with kappa-receptor selec- 
tivity might be a drug class of choice for the relief of the pain and itching caused by 
small cell carcinoma of the lung, which is known to produce large amounts of bombesin- 
like imrnun~reactivity.~~ 
Dynorphin A was proposed as an endogenous ligand for the kappa 
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